TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04976465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Without Anticoagulation
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Without Anticoagulation
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ
Study: NCT03529487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: Oxymetazoline gel applied intra-analy
Study: NCT03888625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ILM Peeling
Description: peeling with complete removal of the internal limiting membrane (ILM)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted ILM Peeling
Description: the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
Study: NCT03394950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butyphthalide combined with rtPA
Description: Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rtPA
Description: Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
Study: NCT03659435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RID-TDS 9.5 mg/24 h
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon® 9.5 mg/24 h
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Study: NCT03738956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment.
Study: NCT01867554

Intervention type: GENETIC
Intervention: gene analysis
Description: gene analysis
Study: NCT03299114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whirlpool

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whirlpool
Study: NCT02014675

Intervention type: DEVICE
Intervention: SD01 ICD lead
Study: NCT01495728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation - Thoracic Spine
Description: Mid and Upper Thoracic Spine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Manipulation
Description: Mid and Upper Thoracic Spine
Study: NCT03114748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS switched OFF and ON
Study: NCT02352142

Intervention type: OTHER
Group type: OTHER
Intervention: Full Term EEG
Description: Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Infant Care
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
Study: NCT01302171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony stimulating factor (GCSF)
Description: 10mcg/kg per day 5 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow mononuclear cells
Description: intra coronary injection of stem cells or placebo
Study: NCT00847613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Study: NCT03022461

Intervention type: OTHER
Intervention: Long term follow-up
Study: NCT04468672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portion size
Description: The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portion size
Description: The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
Study: NCT03080987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 0.3 mg/kg
Description: JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 1.0 mg/kg
Description: JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 1.0 mg/kg
Description: JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 2.5 mg/kg
Description: JNJ-64179375 2.5 mg/kg IV infusion on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 (Dose to be Determined)
Description: JNJ-64179375 IV infusion (Dose to be determined).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375 (Dose to be Determined)
Description: JNJ-64179375 IV infusion (Dose to be determined).
Study: NCT03308630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga based Energy Alignment and Mantra
Description: Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated.
Study: NCT03877406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: addition of empagliflozin 10 MG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemics Oral
Description: dose escalation of hypoglycemics oral
Study: NCT01609283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells
Study: NCT00845429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine - cell based (2007-2008 Formulation)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine - cell-based (2007-2008 Formulation)
Description: 1.0 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus vaccine (2007-2008 Formulation)
Description: 0.5 mL, Intramuscular
Study: NCT02631304

Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
Study: NCT02716376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otovent®
Description: Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
Study: NCT04155879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: Administration of Colchicine at a dose of 0.5mg 2x a day for six months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Electrical or pharmacologic restoration of sinus rhythm
Study: NCT02039557

Intervention type: GENETIC
Intervention: NiCord®/CordIn™ (omidubicel)
Study: NCT02975128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLES system and conventional lumpectomy
Description: Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
Study: NCT03220802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMNI-BiOTiC PPI
Description: The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
Study: NCT00448591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Description: As prescribed
Study: NCT03832530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer conception counseling inclusive of periconception PrEP
Description: Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
Study: NCT02392195

Intervention type: OTHER
Intervention: Non-interventional
Description: Observational
Study: NCT02598323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study: NCT02028715

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Study: NCT03264352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment by current guideline
Description: No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
Study: NCT06164860

Intervention type: OTHER
Group type: OTHER
Intervention: Meditteranean Diet
Description: The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period

Intervention type: OTHER
Group type: OTHER
Intervention: Meditteranean Diet
Description: The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period

Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic Diet
Description: The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.

Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic Diet
Description: The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
Study: NCT01783366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TUBE EXCHANGER
Study: NCT04048096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill Oil
Description: Aker Biomarine Superba Krill Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mixed vegetable oil
Study: NCT02563561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: One dose of apaziquone administered by intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: One dose of apaziquone administered by intravesical administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
Study: NCT02458495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes MAP Intervention
Study: NCT02563561

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
Study: NCT05801315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing
Description: Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth ultrasonic debridement
Description: Peri-implant mucositis sites are treated with thin ultrasonic tips.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full mouth ultrasonic debridement
Description: Peri-implant mucositis sites are treated with thin ultrasonic tips.
Study: NCT00937898

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOLD+ Diet
Description: Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD+ Diet
Description: Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOLD diet
Description: Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD diet
Description: Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
Study: NCT02054117

Intervention type: OTHER
Intervention: Intracerebral Hemorrhage
Description: Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
Study: NCT01610245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Study: NCT04273789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far infrared reflecting sleepwear
Description: 100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sleepwear
Description: 100% microlyocell sleepwear (shorts + shirt)
Study: NCT02541903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilotrif
Description: Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.